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We evaluated the candidate tuberculosis vaccine M72/AS01 in Bacille-Calmette-Guerin (BCG)-vaccinated
infants after or concomitantly with Expanded-Programme-on-Immunization (EPI) vaccines.
Methods: In a Phase-II study in The Gambia (NCT01098474), 2 cohorts of 150 BCG-vaccinated infants
each were randomized 1:1:1. The ‘Outside-EPI’ cohort received one or two M72/AS01 doses, or men-
ingitis vaccine, 1e2 months after primary EPI vaccination. The ‘Within-EPI’ cohort received one or two
M72/AS01 doses concomitantly with the third or last two doses of their primary EPI-regimen, respec-
tively, or EPI vaccines alone. Safety, M72-speciﬁc humoral (ELISA) and cell-mediated (whole-blood ICS)
responses, and humoral responses to EPI vaccines were assessed.
Results: M72/AS01 was acceptably tolerated with no vaccine-related serious adverse events reported.
Seropositivity/seroprotection rates against EPI antigens in the Within-EPI cohort were comparable be-
tween groups, irrespective of M72/AS01 co-administration. Up to one year post M72/AS01 vaccination,
M72-speciﬁc humoral and CD4þ T-cell responses were higher after 2 doses versus 1 dose in both cohorts
(p < 0.0001), and comparable between cohorts after either 1 or 2 doses (p > 0.05).
Conclusion: M72/AS01 given to infants after or concomitantly with EPI vaccines had an acceptable safety
proﬁle. Our results suggest no interference of immunogenicity proﬁles occurred following co-
administration of M72/AS01 and EPI vaccines. Two M72/AS01 doses elicited higher immune responses
than one dose.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Bacille-Calmette-Guerin (BCG) vaccination, which is included in
the Expanded-Programme-on-Immunisation (EPI) schedule in
tuberculosis (TB)-endemic countries, has substantially reduced the1 (Switchboard).
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(O. Ofori-Anyinam), otama@
Ltd. This is an open access article uincidence of severe childhood TB [1]. However, in these countries a
signiﬁcant pulmonary TB incidence still exists among young chil-
dren [2]. Revaccination with BCG does not confer enhanced pro-
tection from TB disease [3e6], and is not recommended by the
WHO [7]. Young children may therefore beneﬁt from a novel efﬁ-
cacious TB vaccine. To make such a vaccine accessible to a popu-
lation of young children, it could, for practical reasons due to the
existing infrastructure, be included in the established EPI regimen.
The TB vaccine candidate M72/AS01 should ideally provide
protective immunity against TB disease in all age groups; to date, it
has been demonstrated to be acceptably tolerated and to elicit
robust immune response in adults and adolescents [8e10].
In adults who received BCG in infancy, two doses of M72/AS01
were required for a robust immune response [9,10]. In infants
however, a two-dose regimen may not be required due to thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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whichmay result in different responses to vaccination as compared
to adults. Because Mtb32A or Mtb39A (the antigens from which
M72 is derived [8,11]) are also found in BCG [12,13], Mtb32A- and
Mtb39A-speciﬁc responses present in BCG-vaccinated infants may
be boosted by vaccinationwith M72/AS01. Integration of M72/AS01
into the EPI scheme may require its co-administration with other
EPI vaccines. Therefore, there is a need to demonstrate the absence
of interference of co-administration on the immunogenicity and
safety of the EPI vaccines and/or M72/AS01.
This controlled study aimed to evaluate the safety, reac-
togenicity and cell-mediated and humoral immunogenicity of M72/
AS01 in BCG-vaccinated infants, either after completion of the EPI
regimen (the ‘Outside-EPI’ cohort) or concomitantly with EPI vac-
cines (the ‘Within-EPI’ cohort). Another study objective was to
describe the immune responses elicited by the EPI vaccines in the
Within-EPI cohort. In each cohort, one or two doses of M72/AS01
were administered to allow comparison of these two different
vaccination regimens, and a control group was included in order to
allow an evaluation of potential interactions between the immune
responses induced by the EPI vaccines and M72/AS01.
2. Methods
2.1. Study design
This Phase-II randomized, controlled, open-label study
(NCT01098474) was conducted from 2010 to 2012 at the Medical
Research Council Unit (MRC) Fajara-Banjul, The Gambia. Study
approval was given by the National Regulatory Authority of The
Gambia and The Gambian Government/MRC Joint Ethics Commit-
tee. The study was conducted in accordance with the Helsinki
Declaration and Good Clinical Practices. A Local Safety Monitor, an
experienced clinician not taking part in the study, was available at
the study site to support the clinical investigators on safety issues.
Written or thumb-printed and witnessed informed consent was
obtained from a parent prior to participation of their child in the
study.Figure 1. Schematic presentation of study design/timeline. Shapes denote time-points of
sampling time-points (ovals). plpv: post last primary vaccination. Men: meningitis vaccine.
5e7 months old at Day 0, had received BCG vaccine at birth and completed the primary EPI
months old at Day 0, and had received HepB vaccine, BCG and OPV at birth, but no other EPI v
of subjects enrolled within each group.Prior to enrollment, study teams met with the community to
describe the study outline. Thereafter, parent(s)/guardian(s) of
children in the eligible age-categories were approached and invited
to the study center. Participants were recruited from the Fajikunda
Health Centre, The Gambia.
Two cohorts of healthy BCG-vaccinated infants (N¼ 150/cohort)
were randomized (1:1:1) using an internet block randomization
(SAS software v8.2) (Figure 1). Infants in the Outside-EPI cohort
were vaccinated after documented completion of EPI vaccination.
Two groups received either 1 or 2 doses (1 month apart) of M72/
AS01. The ﬁrst M72/AS01 dose was administered 4e7 months after
their BCG vaccination, while a third group (controls) received two
doses of a meningitis vaccine one month apart (‘primary vaccina-
tions’), followed by a booster vaccination 6 months later. Infants in
the Within-EPI cohort received 1 or 2 doses of M72/AS01
concomitantly with the third, or the last two doses of their primary
EPI regimen, respectively. The ﬁrst M72/AS01 dose was adminis-
tered 2e4 months after their BCG vaccination, and the control
group received only EPI vaccines (‘primary vaccinations’). Approx-
imately 1 year later, all subjects of the Within-EPI cohort received a
booster dose of the EPI vaccines.
2.2. Study population
Healthy infants were enrolled if they had received one birth
dose each of BCG (administered within 30 days after birth as per
protocol), oral polio vaccine (OPV) and hepatitis B (HepB) vaccine,
in line with the Gambian EPI program. Children in the Outside-EPI
cohort were aged between 5 and 7 months (inclusive) and had to
have completed their primary EPI regimen (diphtheria, tetanus,
pertussis or Haemophilus inﬂuenzae type b (Hib), HepB and pneu-
mococcal vaccines and OPV) at least 1 month prior to planned
vaccinationwith M72/AS01. Subjects of theWithin-EPI cohort were
aged between 2 and 4 months (inclusive) and had not received
their primary EPI vaccines at the time of the ﬁrst study vaccination.
Key exclusion criteria were acute or chronic pulmonary, car-
diovascular, hepatic or renal abnormalities, abnormal laboratory
screening results, major congenital defects, any condition, illness orprimary vaccination (grey squares) or booster vaccinations (white squares), or blood
EPI: DTPw-HepB/Hib vaccines, PCV and OPV. Subjects of the Outside-EPI cohort were
vaccinations at least 1 month before Day 0. Subjects of the Within-EPI cohort were 2e4
accines. Humoral responses were not measured at the 7D plpv time-point. N ¼ number
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evaluations including conﬁrmed or suspected immunosuppressive
or immunodeﬁcient conditions (as determined from medical his-
tory and physical examination - no laboratory testing was
required). Other criteriawere fever or acute disease at enrollment, a
history of hypersensitivity, allergic reactions or anaphylaxis to any
study vaccine (component), or severe malnutrition (weight-for-age
Z-score < -3 standard deviation) [14].
2.3. Study vaccines
M72/AS01 has been described previously [8e10]. One dose-
volume (0.50 mL) of the liposome-based Adjuvant System AS01E
[15,16] (elsewhere in this article referred to as AS01) contained
25 mg ofMPL (3-O-desacyl-40-monophosphoryl lipid A) and 25 mg of
QS-21 (Quillaja saponaria fraction 21; Antigenics Inc, a wholly
owned subsidiary of Agenus Inc.). M72 (10 mg dose) was supplied as
lyophilized antigen for reconstitution with AS01. EPI vaccines in
this study were the combined diphtheria-tetanus-whole cell
pertussis-HepB-Hib vaccine (DTPw-HepB/Hib; Tritanrix Hep B™/
Hiberix™), the 7-valent pneumococcal conjugate vaccine (PCV;
Prevenar/Prevnar™, the 13-valent vaccine was given at booster
since the 7-valent was no longer available and the 13-valent wasTable 1
Antibody responses to EPI vaccine components for the Within-EPI cohort at 1 month po
Abs against EPI
vaccine antigens
Seropositivity/seroprotection
response cutoff
Seropositivity/seroprotec
2-Dose M72/AS01
Value 95% CI
Anti-HBs GMT/GMC 1725.5 [1045.0e2
10 mIU/mLy 95.5 [84.5e99.4
Anti-BPT GMT/GMC 132.1 [116.6e14
15 EU/mL* 100 [91.8e100
Anti-Diphteria GMT/GMC 2.1 [1.6e2.7]
Toxoid 0.1 IU/mLy 100 [91.8e100
Anti-tetanus GMT/GMC 5.5 [4.3e7.1]
Toxoid 0.1 IU/mLy 100 [91.8e100
Anti-PRP GMT/GMC 28.2 [20.3e39.1
0.15 mg/mLy 100 [92.0e100
Anti-Polio 1 GMT/GMC 299.9 [167.6e53
8 ED50* 93.2 [81.3e98.6
Anti-Polio 2 GMT/GMC 458.7 [307.7e68
8 ED50* 97.7 [88.0e99.9
Anti-Polio 3 GMT/GMC 154.8 [100.8e23
8 ED50* 95.5 [84.5e99.4
Anti-S. pneumoniae GMT/GMC 7.7 [6.2e9.7]
 Anti-4 0.05 mg/mL* 100 [91.8e100
0.2 mg/mLy 100 [91.8e100
 Anti-6B GMT/GMC 2.3 [1.4e3.8]
0.05 mg/mL* 100 [92.0e100
0.2 mg/mLy 86.4 [72.6e94.8
 Anti-9V GMT/GMC 5.8 [4.4e7.7]
0.05 mg/mL* 100 [91.8e100
0.2 mg/mLy 100 [91.8e100
 Anti-14 GMT/GMC 3.6 [2.5e5.3]
0.05 mg/mL* 100 [92.0e100
0.2 mg/mLy 100 [92.0e100
 Anti-18C GMT/GMC 7.2 [5.7e9.0]
0.05 mg/mL* 100 [91.8e100
0.2 mg/mLy 100 [91.8e100
 Anti-19F GMT/GMC 5.8 [4.1e8.2]
0.05 mg/mL* 100 [92.0e100
0.2 mg/mLy 97.7 [88.0e99.9
 Anti-23F GMT/GMC 3.2 [2.1e4.8]
0.05 mg/mL* 97.7 [88.0e99.9
0.2 mg/mLy 95.5 [84.5e99.4
GMT/GMC ¼ geometric mean antibody titer/concentration calculated on all subjects. 95%
neutralization.
* Denotes seropositivity cut-offs.
y Denoted seroprotection cut-offs.just introduced in the Gambian EPI) and OPV MRC5 (Polio Sabin™).
The control group of the Outside-EPI cohort received meningitis
vaccine (Menjugate™). Vaccinations were performed either by
intramuscular injection in the left (DTPw-HepB/Hib vaccine) or
right (M72/AS01 or meningitis vaccines) thigh, in the right arm
(PCV), or orally (OPV). All infants had previously received their birth
dose of BCG (Serum Institute of India Ltd).
2.4. Safety and reactogenicity evaluation
Safety was assessed based on the occurrence of solicited local
(injection-site pain and swelling) and general (drowsiness, irrita-
bility, loss of appetite and fever) adverse events (AEs) within 7 days
of vaccination with M72/AS01 and/or control vaccines. Local reac-
togenicity was assessed at the vaccine-speciﬁc administration site.
Unsolicited AEs occurring within 30 days were recorded after each
dose of M72/AS01 or control vaccine and serious AEs (SAEs) until
study end. Reactogenicity assessment was not performed following
the booster vaccinations. Changes in biochemical and hematolog-
ical parameters (complete blood count, creatinine and alanine
aminotransferase [ALT]) were recorded at screening, prior to
vaccination (Day 0), 7 days post each dose with a safety follow-up,
and 1 month, 6 months and approximately one year post lastst last primary vaccination.
tion rate (% of subjects with a GMC value  cut-off)
1-Dose M72/AS01 Control
Value 95% CI Value 95% CI
849.0] 1471.8 [947.5e2286.0] 2153.0 [1468.2e3157.4]
] 97.7 [88.0e99.9] 97.7 [87.7e99.9]
9.5] 139.4 [117.7e164.9] 131.5 [113.5e152.5]
] 100 [92.0e100] 100 [91.8e100]
2.4 [1.8e3.1] 2.5 [2.0e3.1]
] 100 [91.8e100] 100 [91.8e100]
4.8 [3.6e6.4] 6.3 [4.8e8.3]
] 100 [91.8e100] 100 [91.8e100]
] 30.3 [21.8e42.1] 31.2 [21.8e44.7]
] 100 [92.0e100] 100 [91.8e100]
6.7] 397.8 [240.2e658.8] 573.1 [368.7e890.6]
] 97.7 [88.0e99.9] 97.7 [87.7e99.9]
3.7] 524.3 [331.1e830.3] 499.9 [317.7e786.5]
] 95.5 [84.5e99.4] 97.7 [87.7e99.9]
7.8] 103.5 [59.7e179.6] 123.0 [73.6e205.8]
] 86.4 [72.6e94.8] 90.7 [77.9e97.4]
6.4 [5.3e7.8] 8.1 [6.5e10.0]
] 100 [91.8e100] 100 [91.8e100]
] 100 [91.8e100] 100 [91.8e100]
1.5 [0.9e2.4] 1.5 [0.8e2.7]
] 95.3 [84.2e99.4] 93.0 [80.9e98.5]
] 93.0 [80.9e98.5] 81.4 [66.6e91.6]
4.1 [3.0e5.6] 6.0 [4.5e8.1]
] 100 [91.8e100] 100 [91.8e100]
] 100 [91.8e100] 100 [91.8e100]
3.3 [2.3e4.7] 4.2 [2.8e6.2]
] 100 [92.0e100] 100 [91.8e100]
] 97.7 [88.0e99.9] 100 [91.8e100]
5.1 [3.8e7.0] 6.1 [4.2e8.8]
] 100 [92.0e100] 100 [91.8e100]
] 97.7 [88.0e99.9] 97.7 [87.7e99.9]
5.4 [4.2e6.9] 5.9 [4.5e7.5]
] 100 [92.0e100] 100 [91.8e100]
] 100 [92.0e100] 100 [91.8e100]
3.0 [2.0e4.6] 3.8 [2.5e5.7]
] 100 [91.8e100] 97.7 [87.7e99.9]
] 95.3 [84.2e99.4] 97.7 [87.7e99.9]
CI ¼ 95% conﬁdence interval; EU ¼ ELISA unit. ED50: dilution of serum effecting 50%
Figure 2. CONSORT diagram of study ﬂow. Of the 371 subjects screened for the study, 70 subjects were excluded after screening. Reasons for exclusion were: migration from study
area (N ¼ 4), consent withdrawal, not due to an AE (N ¼ 24), did not fulﬁll eligibility criteria (N ¼ 35), because enrollment was completed (N ¼ 6) and travel from the study area
(N ¼ 1). *: one subject of the 1-dose Outside-EPI group withdrew prior to vaccination at Day 0. PLPV: post last primary vaccination. CW: consent withdrawal, not due to an AE.
Other: discontinuation for other reasons. LTF: loss to follow-up/migrated from study area.
O.T. Idoko et al. / Tuberculosis 94 (2014) 564e578 567primary vaccination. AE intensities were scored. Grade 3 (severe)
AEs were deﬁned as those preventing normal activity, swelling
>20 mm in diameter, or axillary temperature >39.0 C.
2.5. Immunogenicity evaluations
Blood samples for immunogenicity evaluations were collected
at Day 0, and 7 days, 1 month, 6 months and approximately 1 year
post last primary vaccination (Figure 1).
2.6. Cell-mediated immune responses
Cell-mediated immune (CMI) responses were evaluated by
whole-blood intracellular cytokine staining (ICS) and ﬂow
cytometry. M72-speciﬁc CD4þ and CD8þ T cells expressing the
immune markers IFN-g and/or IL-2 and/or TNF-a and/or CD40L
were detected using a previously described method [17]. Brieﬂy,Table 2
Demographic characteristics.
Parameter Outside-EPI cohort
2-dose 1-dose Cont
Mean age in months (s.d.) 5.8 (0.68) 5.7 (0.61) 5.7 (
Male/Female (N [%]) 16 [32]/34 [68] 30 [60]/20 [40] 27 [5
Ethnicity (% AFR) 100 100 100
s.d., standard deviation; AFR, African heritage.undiluted whole blood was stimulated in vitro at 37 C with M72
peptides (15-mers overlapping by 11 amino acids; 1.25 mg/mL/
peptide; Eurogentec s.a.), medium (negative control) and positive
control (staphylococcal enterotoxin B; 0.25 mg/mL; Sigma-
eAldrich) for 2 h in the presence of anti-CD28 and anti-CD49d
antibodies. Then, cytokine secretion inhibitor (Golgi Plug; BD
Pharmingen) was added for an additional overnight incubation.
The next day, erythrocytes were lysed and white cells washed and
ﬁxed in FACS Lysing Solution (BD Biosciences) prior to cryopres-
ervation, and stored at 70 C at MRC laboratories until subse-
quent cytometric analysis at GlaxoSmithKline's laboratories
(Rixensart, Belgium). Cells were then thawed in batches, stained
with extracellular markers (CD4 and CD8) (20 min, room tem-
perature), washed, and ﬁxed in Cytoﬁx/Cytoperm solution (BD
Pharmingen) for 20 min at room temperature. The cells were then
permeabilized in Perm/Wash Buffer (BD Biosciences) before
intracellular staining (20 min, room temperature) withWithin-EPI cohort
rol 2-dose 1-dose Control
0.65) 2.1 (0.28) 2.0 (0.19) 2.1 (0.31)
4]/23 [46] 24 [49]/25 [51] 36 [69]/16 [31] 26 [53]/23 [47]
100 100 100
O.T. Idoko et al. / Tuberculosis 94 (2014) 564e578568ﬂuorescent-conjugated antibodies speciﬁc to CD3, CD40L, IL2,
TNF-a, IFN-g (anti-CD3 AF700 [UCTH1], anti-CD4 PerCP [SK3],
anti-CD8 APC-H7 [SK1], anti-CD40L PE [TRAP1], anti-IL2 APC
[MQ1-17H12], anti-TNF-a PE-Cy7 [MAb11], anti-IFNg FITC [B27];
all BD Biosciences). Cells were washed and acquired on an LSRII
ﬂow cytometer (BD Biosciences) and analyzed using FlowJo (Tree
Star Inc) software. ICS results were presented as background-
subtracted percentages of CD4þ and CD8þ T cells, expressing
any combination of IFN-g, IL-2, TNF-a and CD40L.
2.7. Humoral responses
M72-speciﬁc IgG antibodies were measured by enzyme-linked
immunosorbent assay (ELISA) as described previously [8e10].
Antibody titers 2.8 ELISA Units (EU)/mL were considered sero-
positive. For analysis purposes, seronegative subjects were
assigned a value of half the cut-off value (1.4 EU/mL).
Antibody responses speciﬁc to EPI vaccine antigens were
measured for the Within-EPI cohort at 1 month post last primary
vaccination, using in-house developed and validated ELISA assays
for anti-HBsAg, anti-diphtheria, anti-PRP (Hib), anti-tetanus and
anti-BPT antibodies, and antibodies against S. pneumoniae (4/6B/
9V/14/18C/19F/23F serotypes). A microneutralisation assay wasFigure 3. Frequency of solicited local and general adverse events overall by dose (Total va
solicited local and general adverse events (AE) reported within 7 days post vaccination wit
vaccines), are shown for the Outside-EPI (A) and Within-EPI (B) cohorts. Data presented arused for polio 1, polio 2 and polio 3. Seroprotection/seropositivity
cut-offs applied are presented in Table 1.
2.8. Statistical methods
Statistical analyses were conducted using SASv9. Safety analysis
was performed on all subjects for whom at least one vaccine
administration was documented (Total Vaccinated Cohort). The
sample size selected was considered appropriate to deﬁne an initial
safety proﬁle forM72/AS01 vaccination in infants in this Phase-II trial.
Percentages of doses followed by at least one solicited local or
general AE, and proportions of subjects reporting an unsolicited AE
(classiﬁed by the Medical Dictionary for Regulatory Activities
[MedDRA]-preferred term), were tabulated with 95% conﬁdence
interval (CI). Similar analyses were conducted for Grade 3 AEs and
for those with a causal relationship to vaccination, and SAEs were
described. All solicited local AEs were considered to be related to
vaccination. Biochemistry and hematology values outside of pre-
deﬁned reference ranges were recorded and assessed for clinical
signiﬁcance.
Immunogenicity analysis was performed on the According-to-
Protocol (ATP) cohort, comprising all participants who did not
meet any elimination and exclusion criteria during the study andccinated cohort). Percentage of doses with 95% conﬁdence intervals (CI) followed by
h 1 or 2 doses of M72/AS01 or 2 doses of control vaccine (i.e., either meningitis or EPI
e for all subjects for whom at least one vaccine administration was documented.
O.T. Idoko et al. / Tuberculosis 94 (2014) 564e578 569complied with vaccination and blood-sampling schedules, and for
whom immunogenicity data were available. Anti-M72 antibody
responses (calculated as Geometric Mean Concentrations [GMCs]
with 95% CI) at different time-points were compared between
groups using the Satterthwaite t-test assuming unequal variances.
Two groups were considered to be signiﬁcantly different if p 0.05.
Subjects were considered responders to the vaccine if the fre-
quencies of M72-speciﬁc CD4þ or CD8þ T cells expressing at least
two immune markers (amongst CD40L, IFN-g, IL-2 and TNF-a)
exceeded the 95th percentile of pre-vaccination frequencies of all
subjects in this study (found to be equivalent to 0.0268% of CD4þ T
cells and 0.0166% of CD8þ T cells). The Wilcoxon signed-rank test
was used to compare ICS results at different time-points withinTable 3
Unsolicited AEs occurring in more than one subject and associated grade 3 AEs within 3
OUTSIDE-EPI COHORT
Group: 2-dose (N ¼ 50) 1-dose (N
AE n % 95% CI n
All AEs
At least one AE 28 56 (41.3e70) 27
Conjunctivitis 0 0 (0.0e7.1) 0
Eye discharge 0 0 (0.0e7.1) 1
Diarrhoea 8 16 (7.2e29.1) 5
GI disorder 0 0 (0.0e7.1) 1
Vomiting 1 2 (0.1e10.6) 0
Pyrexia 3 6 (1.3e16.5) 1
Furuncle 1 2 (0.1e10.6) 0
Gastroenteritis 0 0 (0.0e7.1) 1
Impetigo 1 2 (0.1e10.6) 0
Otitis media 0 0 (0.0e7.1) 1
Rash pustular 0 0 (0.0e7.1) 1
Resp. tract inf. 21 42 (28.2e56.8) 14
Sepsis 0 0 (0.0e7.1) 0
Septic rash 0 0 (0.0e7.1) 1
Tinea capitis 0 0 (0.0e7.1) 0
URTI 0 0 (0.0e7.1) 2
Cough 0 0 (0.0e7.1) 1
Heat rash 1 2 (0.1e10.6) 0
Grade 3 AEs
At least one AE 0 0 (0.0e7.1) 0
Sepsis 0 0 (0.0e7.1) 0
WITHIN-EPI COHORT
Group 2-dose (N ¼ 47) 1-dose (
AE n % 95% CI n
All AEs
At least one AE 25 53.2 (38.1e67.9) 14
Conjunctivitis 0 0.0 (0.0e7.5) 0
Conjunctivitis
allergic
0 0.0 (0.0e7.5) 0
Diarrhoea 5 10.6 (3.5e23.1) 1
Pyrexia 0 0.0 (0.0e7.5) 2
Acarodermatitis 0 0.0 (0.0e7.5) 0
Body tinea 1 2.1 (0.1e11.3) 0
Candidiasis 0 0.0 (0.0e7.5) 0
Furuncle 1 2.1 (0.1e11.3) 1
Gastroenteritis 1 2.1 (0.1e11.3) 1
Impetigo 1 2.1 (0.1e11.3) 1
Malaria 1 2.1 (0.1e11.3) 0
Otitis media 1 2.1 (0.1e11.3) 0
Resp. tract inf. 15 31.9 (19.1e47.1) 9
Staph. scalded
skin syndr.
1 2.1 (0.1e11.3) 0
Dermatitis atopic 1 2.1 (0.1e11.3) 0
Grade 3 AEs
At least one AE 1 2.1 (0.0e11.3) 0
Gastroenteritis 1 2.1 (0.0e11.3) 0
At least one adverse event (AE) ¼ at least one AE experienced (regardless of the MedDR
% ¼ number/percentage of subjects reporting at least once the symptom; 95% CI ¼ exact
period for solicited AEs were classiﬁed as unsolicited AEs. GI, gastro-intestinal.each group, and the Wilcoxon rank-sum test was used to compare
ICS results between groups.
3. Results
3.1. Population demographics
A total of 371 subjects were screened, and 300 were vaccinated
and randomized into the six groups. Of those, 17 did not complete
the study, mainly because of a consent withdrawal not due to an AE,
or loss to follow-up (Figure 2). Demographics of subjects across
groups in each cohort were comparable in terms of age, gender and
ethnicity (Table 2).0 days after each dose.
¼ 50) Men control (N ¼ 50)
% 95% CI n % 95% CI
54 (39.3e68.2) 26 52 (37.4e66.3)
0 (0.0e7.1) 1 2 (0.1e10.6)
2 (0.1e10.6) 0 0 (0.0e7.1)
10 (3.3e21.8) 2 4 (0.5e13.7)
2 (0.1e10.6) 0 0 (0.0e7.1)
0 (0.0e7.1) 0 0 (0.0e7.1)
2 (0.1e10.6) 4 8 (2.2e19.2)
0 (0.0e7.1) 2 4 (0.5e13.7)
2 (0.1e10.6) 0 0 (0.0e7.1)
0 (0.0e7.1) 0 0 (0.0e7.1)
2 (0.1e10.6) 0 0 (0.0e7.1)
2 (0.1e10.6) 0 0 (0.0e7.1)
28 (16.2e42.5) 19 38 (24.7e52.8)
0 (0.0e7.1) 1 2 (0.1e10.6)
2 (0.1e10.6) 0 0 (0.0e7.1)
0 (0.0e7.1) 1 2 (0.1e10.6)
4 (0.5e13.7) 0 0 (0.0e7.1)
2 (0.1e10.6) 0 0 (0.0e7.1)
0 (0.0e7.1) 0 0 (0.0e7.1)
0 (0.0e7.1) 1 2 (0.1e10.6)
0 (0.0e7.1) 1 2 (0.1e10.6)
N ¼ 52) EPI control (N ¼ 48)
% 95% CI n % 95% CI
26.9 (15.6e41.0) 22 45.8 (31.4e60.8)
0.0 (0.0e6.8) 3 6.3 (1.3e17.2)
0.0 (0.0e6.8) 1 2.1 (0.1e11.1)
1.9 (0.0e10.3) 3 6.3 (1.3e17.2)
3.8 (0.5e13.2) 0 0.0 (0.0e7.4)
0.0 (0.0e6.8) 1 2.1 (0.1e11.1)
0.0 (0.0e6.8) 1 2.1 (0.1e11.1)
0.0 (0.0e6.8) 1 2.1 (0.1e11.1)
1.9 (0.0e10.3) 0 0.0 (0.0e7.4)
1.9 (0.0e10.3) 0 0.0 (0.0e7.4)
1.9 (0.0e10.3) 1 2.1 (0.1e11.1)
0.0 (0.0e6.8) 0 0.0 (0.0e7.4)
0.0 (0.0e6.8) 0 0.0 (0.0e7.4)
17.3 (8.2e30.3) 14 29.2 (17.0e44.1)
0.0 (0.0e6.8) 0 0.0 (0.0e7.4)
0.0 (0.0e6.8) 0 0.0 (0.0e7.4)
0.0 (0.0e6.8) 0 0.0 (0.0e7.4)
0.0 (0.0e6.8) 0 0.0 (0.0e7.4)
A-preferred Term); N ¼ number of subjects with at least one administered dose; n/
95% conﬁdence interval; * Solicited AEs that started outside of the 7-day follow-up
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No safety concerns were identiﬁed, and no vaccine-related SAEs
or withdrawals due to an AE were reported.
In the Outside-EPI cohort, pain was the most frequently re-
ported solicited local AE in all groups (after 4e8% of doses), re-
ported with comparable frequencies between groups (Figure 3A).
No swelling or grade 3 pain was reported. There was no increase in
pain from the ﬁrst to the second dose in any group (data not
shown). Fever was the most frequently reported solicited general
AE (10e19%) in each group. Feverwas also the only solicited general
AE for which grade 3 events were reported (one subject in the
control group reported a fever of 39.6 C one day post dose 2, and
the temperature normalized to 37.2 Cwithin a day). Other solicited
AEs were infrequent (3% across groups).
In theWithin-EPI cohort, pain was the most frequently reported
solicited local AE at each of the injection sites (ie., for M72/AS01,
DTPw-HepB/Hib and Prevnar vaccinations), and for each group
(Figure 3B). Swelling of any intensity and grade-3 swelling were
most frequently reported at the DTPw-HepB/Hib administration
site, irrespective of vaccine group. For the 2-dose M72/AS01 group,
painwas reported comparably at all administration sites. Fever was
most frequently reported (after 28%, 17% and 14% of doses in the 2-
dose, 1-dose and control groups, respectively). Grade 3 irritability
was the only grade 3 solicited general AE reported (2% in the 2-dose
M72/AS01 group).
At least one unsolicited AE was reported by approximately half
of the subjects in each group, except for the 1-dose group of the
Within-EPI cohort, where the incidence was 27% (Table 3). Respi-
ratory tract infection was the most commonly reported AE in both
cohorts. Grade 3 unsolicited AEs included 1 case of sepsis reported
in the control group of the Outside-EPI cohort and 1 case of
gastroenteritis in the 2-dose group of the Within-EPI cohort. None
of these AEs were considered related to study vaccination. In each
cohort, baseline hematological and biochemical parameters were
comparable between groups, and no clinically relevant changes
were reported in the Outside-EPI cohort. In the Within-EPI cohort,
one subject in the 1-dose group reported a grade 3 ALT level 6
months post primary vaccination, which had normalized at the
next visit approximately 6months later, and 1 subject in the control
group reported a grade 3 thrombocytopenia at the last study visit (1
year post primary vaccination), but was determined to be in good
health by the Investigator.
No SAE was considered to be causally related to vaccination. In
the Outside-EPI cohort, 12 SAEs were reported by 8 subjects (2, 3Table 4
SAEs reported during the entire study period.
Cohort Group Age of
onset (month)
Sex Des
Outside-EPI 2-dose 7 F Bro
8 F Ma
12 M Bro
12 M Gas
1-dose 12 F Gas
14 M The
14 M Bro
Control 10 F Cer
11 F Pyr
11 F Ras
7 M Bro
7 M Sep
Within-EPI 2-dose 3 M Gas
1-dose 9 M Feb
Control 11 F Sep
y SAEs marked with the same symbol (*,# or @) were reported in the same subject.and 3 in the 2-dose, 1-dose and control groups, respectively;
Table 4). One subject in the control group of the Outside-EPI cohort
died from sepsis during the primary vaccination phase. In the
Within-EPI cohort, 3 SAEs were reported by 3 subjects (one per
group).
3.3. Antibody responses to EPI vaccine components in the Within-
EPI cohort
Antibody responses speciﬁc to EPI vaccine components (ie., anti-
HB, anti-BPT, anti-diphtheria toxoid, anti-tetanus toxoid, anti-PRP,
anti-polio and anti-S. pneumoniae antibodies) were evaluated in
the Within-EPI cohort at 1 month post last primary vaccination.
Geometric mean responses against EPI antigens were comparable
between the three groups (Table 1/Figure 4). Similarly, in terms of
seropositivity/seroconversion and seroprotection rates, no relevant
differences were observed between groups.
3.4. Anti-M72 IgG responses to M72/AS01
Anti-M72 antibody responses were only observed in the 1-dose
and the 2-dose groups, in which they persisted at 1 year post last
primary vaccination (Figure 5). The highest responses were
measured at 1 month post primary vaccination (1275 and 1264 EU/
mL [2-dose groups] and 8 and 7 EU/mL [1-dose groups] in the
Outside-EPI and Within-EPI cohorts respectively). At each post-
vaccination time-point evaluated, GMCs for the 2-dose groups
were higher relative to the 1-dose groups within each cohort
(p < 0.0001; Satterthwaite test), and GMCs in the Outside-EPI
cohort were not signiﬁcantly different from those in the Within-
EPI cohort when considering the same number of doses adminis-
tered (p > 0.05).
At each post-vaccination time-point evaluated, all subjects in
the 2-dose groups were seropositive for anti-M72 antibodies. In the
1-dose groups of the Outside-EPI and Within-EPI cohorts, sero-
positivity rates ranged from 87% and 89% at 1 month post primary
vaccination, to 75% and 69% at 12 months post primary vaccination,
respectively. At all time-points, seropositivity rates in the 1-dose
groups were comparable between the two cohorts.
3.5. Cell-mediated immune responses to M72/AS01
M72-speciﬁc CD4þ T cells expressing at least two immune
markers (amongst IL-2, IFN-g, TNF-a and CD40-L) were detected
using whole-blood ICS and ﬂow cytometry. Gating strategy andcriptiony Day of
onset
Duration
(days)
Outcome
nchopneumonia* 48 10 Resolved
laria* 51 7 Resolved
nchopneumonia# 168 10 Resolved
troenteritis# 165 8 Resolved
troenteritis 189 11 Resolved
rmal burn 255 14 Resolved
nchopneumonia 276 12 Resolved
ebral malaria@ 88 4 Resolved
exia@ 137 2 Resolved
h@ 130 12 Resolved
nchopneumonia 34 8 Resolved
sis 3 7 Fatal
troenteritis 22 9 Resolved
rile convulsion 153 2 Resolved
sis 230 23 Resolved with
sequelae
Figure 4. Humoral responses against EPI vaccine antigens (Within-EPI cohort). Reverse cumulative distribution curves for the antibody responses speciﬁc to each EPI vaccine
component (ie., anti-HBs, anti-BPT, anti-diptheria toxoid, anti-tetanus toxoid, anti-PRP, anti-polio 1, anti-polio 2 and anti-polio 3 antibodies [A] and antibodies against S. pneumonia.
[B]) were evaluated in the Within-EPI cohort at 1 month post last primary vaccination, using the cut-offs as indicated. Cut-offs for antibodies against S. pneumonia serotypes 4, 9V
and 14 (i.e., 0.05 mg/mL) are not presented due to the X-axis scales used.
Figure 4. (continued).
O.T. Idoko et al. / Tuberculosis 94 (2014) 564e578572
Figure 5. Anti-M72 IgG antibody responses. A. Blood samples were obtained before vaccination (Day 0), as well as 1 month, 6 months and 1 year post last primary vaccination
(plpv). GMC, geometric mean concentration. EU, ELISA Units. CI, conﬁdence interval. The IgG antibody responses were evaluated by M72-speciﬁc ELISA, with a cut-off of 2.8 EU/mL.
Magnitudes of the immune responses between groups were compared using the Satterthwaite t-test. B. Reverse cumulative distribution curves for M72-speciﬁc antibody responses
were evaluated for all groups at 1 month post last primary vaccination.
O.T. Idoko et al. / Tuberculosis 94 (2014) 564e578 573representative scatterplots are presented in Figure 6. At 7 days, 1
month and 6 months post last primary vaccination, the frequencies
in both 2-dose groups, and in the 1-dose group of the Outside-EPI
cohort were signiﬁcantly higher than at prevaccination (p < 0.001
Wilcoxon signed-rank test; Figure 7A) but still relatively low. In
each of these groups, responses persisted at 1 year post last primary
vaccination; p < 0.001 compared to prevaccination levels with the
lowest frequencies in the 1-dose group of the Outside-EPI cohort.
No responses were observed in the control groups.
When considering the same number of doses, the responses
were not signiﬁcantly different between cohorts at each post-
vaccination time-point (p > 0.05). This was illustrated by theresponder rates, using a cut-off of the 95th percentile of pre-
vaccination frequencies of all subjects (Figure 7B). Also, at each
post-vaccination time-point, M72-speciﬁc CD4þ T-cell responses
were signiﬁcantly higher following 2 doses versus 1 dose in both
cohorts (p < 0.0001; Wilcoxon rank-sum test).
Next, the immune-marker (CD40L/IL-2/IFN-g/TNF-a) expression
proﬁles of M72-speciﬁc CD4þ T-cell responses were assessed
(Figure 8). One month post primary vaccination, proportions of
polyfunctional cells were relatively low, with responses mainly
consisting of (single-positive) IL-2þ CD4þ T cells, followed by lower
frequencies of CD40Lþ IL-2þ TNF-aþ CD4þ T cells. Other mono- or
polyfunctional M72-speciﬁc T cells were also present at 7 days and/
Figure 6. Whole-blood intracellular cytokine detection by ﬂow cytometry. Whole-blood intracellular cytokine detection by ﬂow cytometry was performed following overnight
stimulation with the M72 peptide pool, medium (negative control) or Staphylococcus enterotoxin B (SEB; positive control). A. Cytokine production by M72-speciﬁc CD4þ T cells was
determined by discriminating the CD4þ and CD8þ T cells from the “morphological” gating window. B. CD4þ T cells were analyzed with respect to CD40L, IL-2, TNF-a and IFN-g
production. The unstimulated (medium) sample shows background levels of cytokine production. When restimulated with the M72 peptide pool, the production of IL-2 and lower
production of CD40L, TNF-a and IFN-g by CD4þ T cells was detected. The numbers in the quadrant gates of the plots denominate each distinct population based on their cytokine
production. Samples from the same subject are shown at Day 37, which are considered representative of the observed range of responses for all subjects.
O.T. Idoko et al. / Tuberculosis 94 (2014) 564e578574or 1 month post primary vaccination, but did not persist at later
time-points. In both cohorts, two doses were required to elicit these
responses. The two predominating CD4þ T-cell populations per-
sisted at comparable levels at 1 year post primary vaccination.
No M72-speciﬁc CD8þ T-cell responses were observed at any
post-vaccination time-point.
4. Discussion
The considerable incidence of pulmonary TB in young children
in TB-endemic countries could potentially be addressed by
administration of a novel TB vaccine, to be integrated in the EPI
regimen. This study was designed to evaluate the safety, reac-
togenicity and immunogenicity of one and two doses of the
candidate TB vaccine M72/AS01 in BCG-vaccinated infants, given
either after completion of or in co-administrationwith EPI vaccines.
We also aimed to assess whether interference would occur be-
tween the immune responses elicited by EPI vaccines and M72/
AS01 when administered concomitantly. Such interference could
be measured either as an effect of the EPI vaccines on M72-speciﬁc
humoral and CMI responses, or as an effect of M72/AS01 on the
antibody responses speciﬁc to EPI vaccine antigens. Finally, wesought to compare the immunogenicity of the two different M72/
AS01 vaccination regimens in this population.
M72/AS01 had an acceptable safety proﬁle in this population,
and no safety concerns were identiﬁed. In the Outside-EPI cohort,
no grade 3 local AEs were reported, and grade 3 general and un-
solicited AEs were infrequent and reported only in the control
group. In the Within-EPI cohort, grade 3 AEs were reported infre-
quently across all groups. Overall, the unsolicited AEs and SAEs
reported are common to African children of this age group, as
described in similar studies with other vaccines [18,19].
Antibody responses to EPI vaccine antigens were comparable
between groups, irrespective of M72/AS01 (co-)administration.
This suggests that there was no interference of concomitant M72/
AS01 vaccination on the immune responses to the EPI vaccines.
Assuming that the processes that drive antibody responses occur in
the local draining lymph nodes [16], interference would be less
likely given the different vaccination sites. The current ﬁndings are
comparable with those of co-administration studies with other
vaccines (the AS01-adjuvanted malaria candidate vaccine RTS,S/
AS01, and a vector-based TB candidate vaccine), which also sug-
gested the absence of interference [18,19]. It is noted though that
the present study was not powered as a non-inferiority study,
Figure 7. Vaccine-induced M72-speciﬁc CD4þ T-cell responses expressing at least 2 immune markers. Blood samples were obtained before vaccination (Day 0), as well as 7 days, 1
month, 6 months and 1 year post last primary vaccination (plpv). A. Data are reported as the percentages of M72-speciﬁc CD4þ T cells expressing (after in vitro stimulation) at least
two immune markers among IFN-g, IL-2, TNF-a and CD40L of all CD4þ T cells, with ﬁrst and third quartiles, and the minimum/maximum values measured. Magnitudes of the
immune responses between groups were compared using the Wilcoxon rank-sum test. B. Responder rates for the frequency of CD4 T-cells expressing at least 2 immune markers
were calculated using a cut-off of the 95th percentile of the prevaccination frequencies of all subjects (which was equivalent to 0.0268% of CD4þ T cells).
O.T. Idoko et al. / Tuberculosis 94 (2014) 564e578 575because the objective was to provide an initial assessment of the
feasibility of integrating M72/AS01 into the EPI regimen.
The results indicate that there was also no interference of
concomitant EPI vaccination on M72-speciﬁc antibody and CD4þ T-
cell responses, both of whichwere similar between cohorts for each
of the two M72/AS01 dose-regimens. It has been hypothesized that
Th2-biased responses (which may be induced by some of the EPIvaccines [20]), have the potential to interfere with the Th1-biased
responses that can be elicited by a TB candidate vaccine [19]. No
assessment of Th2 cytokines has been performed in the current
study, however, our data do not suggest the presence of such an
effect with M72/AS01.
An additional factor to consider was the time-span between the
administrations of BCG and M72/AS01 (‘boosting interval’), which
Figure 8. M72-speciﬁc CD4þ T-cell responses expressing any combination of immune marker(s) Blood samples were obtained before vaccination (Day 0), as well as 7 days, 1 month,
6 months and 1 year post last primary vaccination (plpv). A. Data are represented in box-and-whiskers plots as percentages of M72-speciﬁc CD4þ T cells expressing any immune
marker among IFN-g, IL-2, TNF-a and CD40L among all CD4þ T cells, with ﬁrst and third quartiles, and the minimum/maximum values measured. B. Phenotypes of M72-speciﬁc
CD4þ T cells expressing (after in vitro stimulation) single markers and any combination of TNF-a, IFN-g, IL-2 and CD40L. Box-and-whiskers plots represent the percentages of CD4þ T
cells with ﬁrst and third quartiles, and the minimum/maximum values measured.
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responses. This may be due to time-related differences in the
magnitudes of BCG-induced memory T-cell responses, as boosting
BCG should preferably take place after effector T-cell responses
have peaked and an established memory population has been
formed [21]. Our results suggest that the 3-month difference in
boosting intervals between cohorts did not affect the immunoge-
nicity of M72/AS01. Pre-existing Mtb32A- and Mtb39A-speciﬁc
CD4þ T-cell responses were not detected, even though BCG-
induced CD4þ T-cell responses reportedly peak 6e10 weeks post
vaccination [21].
Another factor that could have inﬂuenced the immune re-
sponses was the exposure to environmental mycobacteria, which
may have been longer for the infants in the Outside-EPI cohort
relative to those in the Within-EPI cohort. Such exposure has been
reported in preclinical and clinical studies to be able to negatively
affect immune responses to BCG [22e25], and this could in turn
reduce the M72/AS01-induced immune responses, as well as the
humoral responses to some of the antigens in EPI vaccines (e.g.,
HepB vaccine and OPV [26]). No evidence of these effects was
observed in the present study.
After primary vaccination, M72-speciﬁc CD4þ T-cell responses
were signiﬁcantly higher after two M72/AS01 doses than after one,
even up to 1 year post vaccination, in both cohorts. Moreover, at 1
year post vaccination, CMI responses induced by one M72/AS01
dose were down to baseline, indicating that one dose of M72/AS01
is insufﬁcient tomount an adequate persistent immune response in
this population either without or in co-administration with the EPI
vaccines.
The immaturity of the neonatal immune system is character-
ized by, amongst others, a diminished IFN-g secretion by lym-
phocytes and impaired responses to several Toll-like receptor
(TLR) ligands, such as the TLR4 ligand MPL which is present in
AS01 [20,27e30]. Nonetheless, our results demonstrate the ability
of M72/AS01 to induce CD4þ T-cell responses in this population.
Proportions of polyfunctional M72-speciﬁc CD4þ T cells (express-
ing 2 immune markers among CD40L, IL-2, TNF-a and IFN-g) out
of the total of responding CD4þ T cells were initially low, but
modestly increased post second dose. Compared to the present
results, there was a tendency towards higher proportions of M72/
AS01-induced polyfunctional CD4þ T cells in adults [9,10] and
adolescents (unpublished results) in endemic countries. This dif-
ference could be partly due to the lower expression of CD40L
observed in the infant population, relative to the adult and
adolescent populations. The clinical relevance of these differences
are unclear, as not only different statuses of the immune system
between the populations, but also multiple other differences in
study conditions and methodologies may play a role (e.g., whole-
blood versus peripheral blood mononuclear cell-based ICS, the
comparability of which is uncertain [31e34]). Most importantly,
interpretation of the clinical relevance of these results is hampered
by the absence of universally recognized correlates of protection,
although several preclinical challenge studies have suggested that
the presence of polyfunctional T cells is associated with protection
against TB disease [35e38].
5. Conclusions
The M72/AS01 candidate TB vaccine had a clinically acceptable
safety proﬁle when administered in infants either after or
concomitantly with EPI vaccines. Within the context of this trial,
there was no interference by co-administration of M72/AS01 and
EPI vaccines on their respective immunogenicity proﬁles. Two
doses of M72/AS01 induced higher M72-speciﬁc immune re-
sponses compared to one dose.Acknowledgments
The authors thank Alison Sanneh and Archibald Worwui (MRC)
for local clinical trial management and managing the local utility
database, respectively, Pa Kinteh (lab technician, MRC), and all ﬁeld
workers and nurses involved in this study. They also thank Paul
Gillard, Didier Lapierre and Pascal Mettens (GSK), Simon Donkor
(MRC), and Jerry Sadoff and Bruce McClain (formerly AERAS) for
helpful discussions, Micha€el Mestre (GSK) for his contributions to
the ICS assays, Evi de Ruymaecker (GSK) for overall study man-
agement, An Ranquin and Jyothsna Krishnan (GSK) for writing the
clinical study report and protocol, respectively, Ellen Oe (XPE
Pharma&Science on behalf of GSK) for writing assistance during
the development of the manuscript, and Soﬁa Dos Santos-Mendes
(XPE Pharma&Science on behalf of GSK) and Ulrike Krause for
publication management.
GlaxoSmithKline Biologicals S.A. and AERAS were the funding
sources. The corresponding author had full access to the data and
was responsible for submission of the publication.
Trademarks
Tritanrix Hep B, Hiberix, Polio Sabin are trademarks of the
GlaxoSmithKline group of companies. Prevenar/Prevnar is a
trademark of Wyeth LLC. Menjugate is a trademark of Novartis AG.
Contributorship
All authors participated in the design, or implementation, or
analysis and interpretation of the study results; as well as in the
development of this manuscript. All authors had full access to the
data and gave ﬁnal approval before submission. M.O.O. was the
coordinating investigator and together with O.T.I., O.A.O., P.K.O.,
A.O. and E.O., was responsible for the conduct of the trial. A.B. was
responsible for the statistical input. O.O.-A. led the clinical team;
M.-A.D. was the project leader; and Ph.M. and E.J. led the laboratory
analysis. The corresponding author was responsible for submission
of the publication.
Funding: None.
Competing interests: Ph.M., A.B., E.J., M.-A.D. and O.O.-A. are
employees of GlaxoSmithKline group of companies (GSK). Ph.M.,
E.J., M.-A.D. and O.O.-A. own stock options or restricted shares in
GSK. All other authors report no potential conﬂicts.
GlaxoSmithKline Biologicals S.A., as sponsor of the study, was
involved in all stages of the study conduct and analysis.
Ethical approval: Not required.
References
[1] Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The
efﬁcacy of bacillus Calmette-Guerin vaccination of newborns and infants in
the prevention of tuberculosis: meta-analyses of the published literature.
Pediatrics 1995;96:29e35.
[2] World Health Organization. Global tuberculosis control: WHO report 2013;
2013. WHO/HTM/TB/2013.11:1-289.
[3] Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, et al.
Effect of BCG revaccination on incidence of tuberculosis in school-aged chil-
dren in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005;366:
1290e5.
[4] Sepulveda RL, Parcha C, Sorensen RU. Case-control study of the efﬁcacy of BCG
immunization against pulmonary tuberculosis in young adults in Santiago,
Chile. Tuber Lung Dis 1992;73:372e7.
[5] Leung CC, Tam CM, Chan SL, Chan-Yeung M, Chan CK, Chang KC. Efﬁcacy of the
BCG revaccination programme in a cohort given BCG vaccination at birth in
Hong Kong. Int J Tuberc Lung Dis 2001;5:717e23.
O.T. Idoko et al. / Tuberculosis 94 (2014) 564e578578[6] Karonga Prevention Trial Group. Randomised controlled trial of single BCG,
repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for
prevention of leprosy and tuberculosis in Malawi. Lancet 1996;348:17e24.
[7] World Health Organization. Global tuberculosis program and global pro-
gramme on vaccines: statement on BCG revaccination for the prevention of
tuberculosis; 1995. p. 229e36.
[8] Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitie M-A, Mettens P,
et al. Improved CD4þ T cell responses to Mycobacterium tuberculosis in PPD-
negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/
AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine
2013;31:2196e206.
[9] Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, et al.
Induction and regulation of T-cell immunity by the novel TB vaccine M72/
AS01 in South African adults. Am J Respir Crit Care Med 2013;188:492e502.
[10] Montoya J, Solon JA, Cunanan SR, Acosta L, Bollaerts A, Moris P, et al.
A randomized, controlled dose-ﬁnding phase II study of the M72/AS01
candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol
2013;33:1360e75.
[11] Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al.
Differential immune responses and protective efﬁcacy induced by compo-
nents of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA
or recombinant protein. J Immunol 2004;172:7618e28.
[12] Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T, et al.
Molecular characterization and human T-cell responses to a member of a
novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999;67:
2941e50.
[13] Skeiky YA, Lodes MJ, Guderian JA, Mohamath R, Bement T, Alderson MR, et al.
Cloning, expression, and immunological evaluation of two putative secreted
serine protease antigens of Mycobacterium tuberculosis. Infect Immun
1999;67:3998e4007.
[14] World Health Organization. WHO global database on child growth and
malnutrition; 1997. http://libdoc.who.int/hq/1997/WHO_NUT_97.4.pdf.
[15] Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in
vaccines: concepts, achievements and perspectives. Expert Rev Vaccines
2007;6:723e39.
[16] Garçon N, Van Mechelen M. Recent clinical experience with vaccines using
MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011;10:
471e86.
[17] Díez-Domingo J, Garces-Sanchez M, Baldo JM, Planelles MV, Ubeda I, JuBert A,
et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1)
AS03-adjuvanted prepandemic candidate inﬂuenza vaccines in children aged
3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J
2010;29:e35e46.
[18] Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R,
et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria
candidate vaccine when integrated in the expanded program of immuniza-
tion. J Infect Dis 2010;202:1076e87.
[19] Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, et al.
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coad-
ministration with EPI vaccines in a randomized controlled trial in Gambian
infants. Sci Transl Med 2011;3:88ra56.
[20] Marchant A, Goldman M. T cell-mediated immune responses in human
newborns: ready to learn? Clin Exp Immunol 2005;141:10e8.
[21] Soares AP, Kwong Chung CK, Choice T, Hughes EJ, Jacobs G, van Rensburg EJ,
et al. Longitudinal changes in CD4þ T-cell memory responses induced by BCG
vaccination of newborns. J Infect Dis 2013;207:1084e94.[22] Fine PE. Variation in protection by BCG: implications of and for heterologous
immunity. Lancet 1995;346:1339e45.
[23] Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al. BCG-
induced increase in interferon-gamma response to mycobacterial antigens
and efﬁcacy of BCG vaccination in Malawi and the UK: two randomised
controlled studies. Lancet 2002;359:1393e401.
[24] Andersen P, Doherty TM. The success and failure of BCG e implications for a
novel tuberculosis vaccine. Nat Rev Microbiol 2005;3:656e62.
[25] Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R,
et al. Failure of the Mycobacterium bovis BCG vaccine: some species of envi-
ronmental mycobacteria block multiplication of BCG and induction of pro-
tective immunity to tuberculosis. Infect Immun 2002;70:672e8.
[26] Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, et al.
Inﬂuence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and
cytokine responses to human neonatal vaccination. J Immunol 2002;168:
919e25.
[27] Marodi L. Innate cellular immune responses in newborns. Clin Immunol
2006;118:137e44.
[28] Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective
impairment of TLR-mediated innate immunity in human newborns: neonatal
blood plasma reduces monocyte TNF-a induction by bacterial lipopeptides,
lipopolysaccharide, and imiquimod, but preserves the response to R-848.
J Immunol 2004;173:4627e34.
[29] Vanden Driessche K, Persson A, Marais BJ, Fink PJ, Urdahl KB. Immune
vulnerability of infants to tuberculosis. Clin Dev Immunol 2013;2013:781320.
[30] Flanagan KL, Burl S, Lohman-Payne BL, Plebanski M. The challenge of assessing
infant vaccine responses in resource-poor settings. Expert Rev Vaccines
2010;9:665e74.
[31] Maecker HT, Rinfret A, D'Souza P, Darden J, Roig E, Landry C, et al. Stan-
dardization of cytokine ﬂow cytometry assays. BMC Immunol 2005;6:13.
[32] Suni MA, Picker LJ, Maino VC. Detection of antigen-speciﬁc T cell cytokine
expression in whole blood by ﬂow cytometry. J Immunol Methods 1998;212:
89e98.
[33] Deenadayalan A, Maddineni P, Raja A. Comparison of whole blood and PBMC
assays for T-cell functional analysis. BMC Res Notes 2013;6:120.
[34] De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F,
et al. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-
gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC
stimulation. Cytokines 1992;4:239e48.
[35] Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, Arnett K, et al. Protection
and polyfunctional T cells induced by Ag85B-TB10.4/IC31® against Mycobac-
terium tuberculosis is highly dependent on the antigen dose. PLoS One 2009;4:
e5930.
[36] Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al.
Multifunctional TH1 cells deﬁne a correlate of vaccine-mediated protection
against Leishmania major. Nat Med 2007;13:843e50.
[37] Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al.
Tuberculosis subunit vaccination provides long-term protective immunity
characterized by multifunctional CD4 memory T cells. J Immunol 2009;182:
8047e55.
[38] Forbes EK, Sander C, Ronan E, McShane H, Hill AVS, Beverley PCL, et al. The
presence of multifunctional, high-cytokine-producing Th1 cells in the lung,
but not spleen, correlate with protection against Mycobacterium tuberculosis
aerosol challenge in mice. J Immunol 2008;181:4955e64.
